• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Firmenich to acquire senomyx, pioneer in taste innovation

Share:

September 24, 2018

Firmenich and Senomyx, Inc. today announced that they have entered into a definitive merger agreement under which Firmenich will acquire all of the outstanding common stock of Senomyx for $1.50 per share in cash. This represents a premium of approximately 43% over Senomyx’s closing price on September 14, 2018 and a premium of approximately 39% based on the prior 30-trading day volume-weighted average price. The proposed transaction has been unanimously approved by the Boards of Directors of both Firmenich and Senomyx. The companies expect to close the transaction in the fourth quarter of 2018.

“Senomyx has established itself as a leader in taste innovation and a recognized pioneer in sweet, cooling and bitter solutions,” said Patrick Firmenich, Chairman of the Board, Firmenich. “Building on our long-term partnership spanning more than a decade, we look forward to welcoming Senomyx into Firmenich to lead in taste and nutrition.”

“We are excited to be joining Firmenich,” stated John Poyhonen, President and Chief Executive Officer of Senomyx. “Firmenich’s commitment to innovation and delivery of world-class commercialization capabilities combined with our long standing relationship makes this deal the ideal fit for our companies. We believe this merger will allow the Senomyx discoveries to reach their full potential. I would like to personally thank all our employees for their dedication and contributions in building a leading proprietary taste science technology platform that will benefit consumers around the globe well into the future.”

“Building on our world-class science and pioneering taste platform, this strategic acquisition confirms our commitment to being the partner of choice in taste and nutrition,” said Gilbert Ghostine, CEO Firmenich. “Adding Senomyx’s leading taste technologies and strong natural ingredients pipeline to our taste platform, uniquely positions us to create healthy and great tasting food, drink and oral care experiences for our customers.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Upon closing, Senomyx will be integrated into Firmenich’s North America Research & Development organization and its products will be commercialized through its Taste Platform. Senomyx R&D operations will remain in San Diego, with a continued focus on discovering and developing world-class flavor and sweetener solutions for the world’s greatest brands. Firmenich looks forward to continuously advancing Senomyx’s innovative pipeline of products and its discovery capabilities to shape the most differentiating natural taste solutions for its customers. Innovation-driven and recognized for its world-class ingredient screening capabilities, Senomyx recently identified and has started to develop a high intensity and a clean tasting sweetener, Siratose, which naturally occurs in Monkfruit.

Under the terms of the merger agreement, Firmenich will promptly commence a tender offer to acquire all of the outstanding shares of Senomyx common stock for $1.50 per share in cash. Following the successful completion of the tender offer, Firmenich will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price as to be paid to stockholders tendering their shares in the tender offer. The tender offer is expected to expire at one minute following 11:59 p.m., Eastern Time, on the 20th business day after the launch of the tender offer, unless extended in accordance with the merger agreement and the applicable rules and regulations of the Securities and Exchange Commission.

The consummation of the tender offer is subject to various conditions, including a minimum tender of a majority of outstanding Senomyx shares and other customary conditions.

Senomyx’s financial advisors for the transaction are Needham & Company and Conexus Capital Advisors with Cooley LLP providing legal advice. Firmenich’s financial advisor for the transaction is Piper Jaffray with Duane Morris LLP providing legal advice.

Date: September 24, 2018

Source: Yahoo Finance

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • iGambit And Clinigence Holdings Announce Transformational MergeriGambit And Clinigence Holdings Announce Transformational Merger
  • Vaxil Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.Vaxil Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.
  • BioIntelliSense Awarded FDA 510(k) Clearance for On-Body Sensor for Scalable Remote CareBioIntelliSense Awarded FDA 510(k) Clearance for On-Body Sensor for Scalable Remote Care
  • Celgene Wins Approval for Drug key to Bristol BuyoutCelgene Wins Approval for Drug key to Bristol Buyout
  • 10 Best Life Sciences Stocks For This Year – Top Stocks – TheStreet Ratings10 Best Life Sciences Stocks For This Year – Top Stocks – TheStreet Ratings
  • Denials Management Named Most Time-Consuming Task in RCMDenials Management Named Most Time-Consuming Task in RCM
  • Cleveland Clinic Study: Propeller Health’s Smart Inhalers Reduces Hospitalizations, ER Visits for COPD PatientsCleveland Clinic Study: Propeller Health’s Smart Inhalers Reduces Hospitalizations, ER Visits for COPD Patients
  • VR startup Karuna Labs Raises $3 Million in Seed Funding to Help Over 30 Million Americans Suffering From Chronic PainVR startup Karuna Labs Raises $3 Million in Seed Funding to Help Over 30 Million Americans Suffering From Chronic Pain

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications